NCCN recognizes the importance of the availability of and access to shared resources in conducting research. Such resources include complex technologies, instrumentation facilities, human tissue specimens, animal models and specialized databases. While each NCCN Member Institution has core resources, the number and types of resources vary from center to center. This database was established to enable our cancer centers to share their shared resources collectively as a means to make available to scientists and investigators resources that will improve the ability to conduct research and thereby facilitate scientific progress. New resources to advance cancer research will be added as they become available.
To use this website, you must be a registered user on the NCCN website.
If your cancer center is interested in listing your shared resources on this site, please contact Donna Scharff at firstname.lastname@example.org .
Bioanalytical Methods Available at the Bioanalytics, Metabolomics and Pharmacokinetics (BMPK) Shared Resource of Roswell Park Comprehensive Cancer Center
From the discovery stage to preclinical research through clinical development, our bioanalytical laboratories are here to help you achieve your research objectives by delivering high quality results in a timely manner. Our experienced staff can develop and validate new bioanalytical methods using a variety of techniques to quantitate drug and metabolite concentrations in a variety of animal and human matrices (e.g., cell pellets, media, plasma, serum, cerebrospinal fluid (CSF), urine, and tissue). The following is a listing of our non-proprietary methods arranged by compound name. Validated methods are those whose acceptance criteria are consistent with FDA’s Bioanalytical Method Validation Guidance for Industry while qualified methods are discovery based methods that have undergone less stringent testing. Our overall goal is to help ensure that you meet your critical deadlines and advance your aims to the next level.
Tumor Imaging Metrics Core and Precision Imaging Metrics
A shared resource of the Dana-Farber/Harvard Cancer Center
The Tumor Imaging Metrics Core (TIMC), co-Directed by Annick D. Van den Abbeele, MD (DFCI) and Gordon J. Harris, PhD (MGH), is a shared resource that was founded in 2004 to provide standardized, longitudinal tumor metrics of radiological scans (CT, MR and PET) for patients enrolled in oncologic clinical trials across the five Harvard teaching hospitals of the Dana-Farber/Harvard Cancer Center (DF/HCC). The independent web-based tumor response measurements provided by the Core facilitate the evaluation of new therapies tested and/or developed at DF/HCC and other Cancer Centers.
There are currently over two dozen clinical trials imaging criteria in common use, and most trials have further complications of trial-specific criteria modifications and even multiple imaging criteria within a trial. As a result, many cancer centers struggle to get imaging assessments performed correctly according to the trial specific imaging criteria in time for the patient’s office visit where results are needed to determine subject enrollment and continuance on trial. Furthermore, stringent audit requirements are taxing on cancer center staff, and without a comprehensive informatics platform to manage the imaging data, these can be time consuming and poor data quality and tracking can lead to protocol violations.
To address these issues and more, we developed a web-viewer based system to manage the entire clinical trials imaging workflow including ordering, communication, image assessments, criteria conformance, results reporting, electronic signatures, audit trails, and chargeback billing. These full range of tasks are all managed through an integrated web informatics platform, the Precision Imaging Metrics system (PIMS), developed by TIMC. This software platform is currently in use at eight NCI-designated Cancer Centers around the country, including several NCCN sites, with several additional NCCN and other Cancer Centers considering implementing the system. PIMS guides radiological review so that clinical trials imaging assessment results are provided with high-quality data compliant with the trial-specific protocol criteria. The workflow management tools ensure that results are available on-line in time for review at the point of care often on the same day after completion of scanning.
For most of our larger collaborating Cancer Centers, imaging assessments are performed by the participating site radiology team using the PIMS imaging assessment and workflow management system. Alternatively, smaller cancer centers often prefer to send scans electronically to TIMC to perform imaging assessments and cancer center staff at the sites can place orders and review results, including annotated images, tables, and graphs, in the Precision Imaging Metrics web portal. TIMC currently manages imaging for over 1,000 active clinical trials and performs over 17,000 image assessments per year. The figure below shows the PIMS web-based informatics and workflow management system on the left and the integrated oncology clinical trials imaging assessment web-viewer on the right.
For more information on our clinical trials services or to contact the Tumor Imaging Metrics Core, visit our website.